Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Breast Disease(Electronic Edition) ›› 2007, Vol. 01 ›› Issue (02): 25-27. doi: 10.3877/cma.j.issn.978-7-900220-07-3.2007.02.008

• Experimental Research • Previous Articles     Next Articles

Expression of CD105, FⅧ, CD31 and CD34 in evolution of breast carcinoma

Jiang-yu ZHANG1, Qi WANG1, Cai-xia ZHU1, Wen-ping LI1, Jia-li ZHANG1, Zhong-yang CHEN1, Wen-jing CHEN1   

  1. 1.Guangdong Women and Children Hospital, Guangzhou Medical College, Guangzhou 510010, China
  • Online:2007-02-25 Published:2024-12-04

Abstract:

Objective

To detect the changes of new vessels in the evolution of breast carcinoma so as to select a better new vessel endothelial cells marker.

Methods

By using immunohistochemistry the breast tissues of 100 patients including 20 cases of atypical ductal hyperplasia (ADH), 20 cases of ductal carcinoma in situ(DCIS),20 cases of microductal carcinoma (MDC) and 40 cases of infiltrating ductal carcinoma (IDC, NOS)were stained with anti-CD105, FⅧ, CD31 and CD34 antibodies, then the microvessel density (MVD) was calculated.

Results

The MVD of CD105 was 8.25 ±5.78,10.05 ±4.23,25.35 ±7.62 and 37.33 ±5.86 in ADH,DCIS, MDC and IDC (NOS), respectively ( P <0.05), while that of FⅧwas 10.60 ±8.99, 16.60 ±3.47,16.90 ±5.62 and 17.90 ±5.62, that of CD31 was 6.80 ±3.90, 19.40 ±4.58, 20.74 ±6.67 and 22.74 ±6.67, and that of CD34 was 14.40 ±12.82,25.20 ±5.39,26.32 ±4.89 and 40.32 ±4.89.

Conclusions

To assess the expression of new vessels in the progression of breast carcinoma, MVD detected by CD105 maybe more valuable, it will provide theoretical evidence for the clinical application of anti-vessel inhibitor.

Key words: Breast neoplasms; CD105; MVD; FⅧ; Antigens, CD31; Antigens, CD34

京ICP 备07035254号-13
Copyright © Chinese Journal of Breast Disease(Electronic Edition), All Rights Reserved.
Tel: 0086-10-51322630 E-mail: jcbd@medmail.com.cn
Powered by Beijing Magtech Co. Ltd